Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, et al.
New England Journal of Medicine (2017) Vol. 377, Iss. 20, pp. 1919-1929
Open Access | Times Cited: 3826

Showing 26-50 of 3826 citing articles:

Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng, Wen Jiang, Betty Y.S. Kim, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 10, pp. 568-586
Open Access | Times Cited: 744
Toward personalized treatment approaches for non-small-cell lung cancer
Meina Wang, Roy S. Herbst, Chris Boshoff
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1345-1356
Closed Access | Times Cited: 700
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 681
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Haiying Lu, Qiaodan Zhou, Jun He, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 629
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano‐Goroff, Allison Betof Warner, Jedd D. Wolchok
Cell Research (2020) Vol. 30, Iss. 6, pp. 507-519
Open Access | Times Cited: 609
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan, Lili Huang, Jianhua Chen, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 602
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl, Michael Untch, Nicole Burchardi, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1279-1288
Open Access | Times Cited: 567
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 147-164
Closed Access | Times Cited: 559
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
Deborah Blythe Doroshow, Miguel F. Sanmamed, Katherine Hastings, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 15, pp. 4592-4602
Open Access | Times Cited: 557
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 491-503
Closed Access | Times Cited: 552
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani, et al.
JAMA Oncology (2019) Vol. 5, Iss. 10, pp. 1431-1431
Open Access | Times Cited: 550
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 544
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
JAMA Oncology (2020) Vol. 6, Iss. 5, pp. 661-661
Open Access | Times Cited: 532
Dermatologic Reactions to Immune Checkpoint Inhibitors
V. Sibaud
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 345-361
Closed Access | Times Cited: 503
Advances in cancer immunotherapy 2019 – latest trends
Stephan Krüger, Matthias Ilmer, Sebastian Kobold, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 500
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon, Nadia Yousaf, Nicolò Matteo Luca Battisti, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 9, pp. e447-e458
Closed Access | Times Cited: 494
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal Patel, Andy J. Minn
Immunity (2018) Vol. 48, Iss. 3, pp. 417-433
Open Access | Times Cited: 493
The growing role of precision and personalized medicine for cancer treatment
Paulina Krzyszczyk, Alison Acevedo, Erika J. Davidoff, et al.
Deleted Journal (2018) Vol. 06, Iss. 03n04, pp. 79-100
Open Access | Times Cited: 484
Comprehensive analysis of the clinical immuno-oncology landscape
Jun Tang, A. Shalabi, Vanessa M. Hubbard-Lucey
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 84-91
Open Access | Times Cited: 471
Update 2020: Management of Non-Small Cell Lung Cancer
Mariam Alexander, So Yeon Kim, Haiying Cheng
Lung (2020) Vol. 198, Iss. 6, pp. 897-907
Open Access | Times Cited: 465
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge, Robert C. Doebele, Keith M. Kerr
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 6, pp. 341-355
Closed Access | Times Cited: 451
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 4, pp. 450-462
Closed Access | Times Cited: 440
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jian-Ming Xu, Yun Zhang, Ru Jia, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 2, pp. 515-523
Open Access | Times Cited: 435
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu, Zhongkai Gu, Chen Yang, et al.
Computational and Structural Biotechnology Journal (2019) Vol. 17, pp. 661-674
Open Access | Times Cited: 433
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 430

Scroll to top